# Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis

> **NCT06487715** · PHASE2 · UNKNOWN · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 42 (estimated)

## Conditions studied

- Gastric Cancer Peritoneal Metastases

## Interventions

- **DRUG:** albumin-bound paclitaxel (260 mg/m2, d1)
- **DRUG:** S-1
- **DRUG:** sintilimab
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT06487715
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-01
- **Primary completion:** 2025-03-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2024-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06487715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06487715, "Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06487715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*